Originally published as JCO Early Release 10.1200/JCO.2006.08.3089 on February 5 2007
Journal of Clinical Oncology, Vol 25, No 7 (March 1), 2007: pp. 799-804
© 2007 American Society of Clinical Oncology.
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
Michael R. Grever,
David M. Lucas,
Gordon W. Dewald,
Donna S. Neuberg,
John C. Reed,
Shinichi Kitada,
Ian W. Flinn,
Martin S. Tallman,
Frederick R. Appelbaum,
Richard A. Larson,
Elisabeth Paietta,
Diane F. Jelinek,
John G. Gribben,
John C. Byrd
From the Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH; Department of Cytogenetics, Mayo Clinic; Mayo Clinic College of Medicine, Rochester, MN; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; Burnham Institute for Medical Research, La Jolla, CA; Department of Oncology, Johns Hopkins University, Baltimore, MD; Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine; The University of Chicago, Chicago IL; Fred Hutchinson Cancer Research Center, Seattle, WA; Our Lady of Mercy Comprehensive Cancer Center, Bronx, NY; and Barts and The London School of Medicine, London, United Kingdom
Address reprint requests to Michael R. Grever, MD, 215 Means Hall, 1654 Upham Dr, Columbus, OH 43210; e-mail: michael.grever{at}osumc.edu
Purpose Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome.
Patients and Methods We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients.
Results Complete response (CR) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P = .00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL; P < .0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P = .0002) or del(11q22.3) (hazard ratio, 1.904; P = .006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgVH mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS.
Conclusion These results support the use of interphase cytogenetic analysis, but not IgVH, CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies.
published online ahead of print at www.jco.org on February 5, 2007.
Supported by National Institutes of Health Grants No. R01 CA 88647 (M.R.G.) and U10 CA 101140, and R21 CA 101332 (J.C.B.).
Presented in part at annual meetings of the American Society of Hematology, December 6-10, 2002 (Philadelphia, PA), December 6-9, 2003 (San Diego, CA), and December 4-7, 2004 (San Diego, CA); and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. G. Johnson, P. D. Sherrington, A. Carter, K. Lin, T. Liloglou, J. K. Field, and A. R. Pettitt
A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene
Cancer Res.,
June 15, 2009;
69(12):
5210 - 5217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, J. D. Shin, M. A. Vargo, M. E. Davis, D. M. Rozewski, A. J. Johnson, B.-N. Su, et al.
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
Blood,
May 7, 2009;
113(19):
4656 - 4666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Chen, W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi, and W. Plunkett
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
Blood,
May 7, 2009;
113(19):
4637 - 4645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Zenz, J. Mohr, E. Eldering, A. P. Kater, A. Buhler, D. Kienle, D. Winkler, J. Durig, M. H. J. van Oers, D. Mertens, et al.
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Blood,
April 16, 2009;
113(16):
3801 - 3808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hewamana, T. T. Lin, C. Rowntree, K. Karunanithi, G. Pratt, R. Hills, C. Fegan, P. Brennan, and C. Pepper
Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
February 10, 2009;
27(5):
763 - 769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al.
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Clin. Cancer Res.,
February 1, 2009;
15(3):
995 - 1004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. T. Awan, N. E. Kay, M. E. Davis, W. Wu, S. M. Geyer, N. Leung, D. F. Jelinek, R. C. Tschumper, C. R. Secreto, T. S. Lin, et al.
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Blood,
January 15, 2009;
113(3):
535 - 537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Y. H. Hallaert, A. Jaspers, C. J. van Noesel, M. H. J. van Oers, A. P. Kater, and E. Eldering
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Blood,
December 15, 2008;
112(13):
5141 - 5149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells
Haematologica,
December 1, 2008;
93(12):
1843 - 1851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Pepper, T. T. Lin, G. Pratt, S. Hewamana, P. Brennan, L. Hiller, R. Hills, R. Ward, J. Starczynski, B. Austen, et al.
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
Blood,
November 1, 2008;
112(9):
3807 - 3817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al.
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
J. Clin. Oncol.,
October 20, 2008;
26(30):
4912 - 4920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Zenz, A. Krober, K. Scherer, S. Habe, A. Buhler, A. Benner, T. Denzel, D. Winkler, J. Edelmann, C. Schwanen, et al.
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Blood,
October 15, 2008;
112(8):
3322 - 3329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Rath, C. Geisler, C. B. Christiansen, N. Hastrup, H. O. Madsen, M. K. Andersen, L. B. Pedersen, and J. Jurlander
Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease
Haematologica,
September 1, 2008;
93(9):
1424 - 1426.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Trachootham, H. Zhang, W. Zhang, L. Feng, M. Du, Y. Zhou, Z. Chen, H. Pelicano, W. Plunkett, W. G. Wierda, et al.
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism
Blood,
September 1, 2008;
112(5):
1912 - 1922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood,
August 15, 2008;
112(4):
965 - 974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Blood,
June 15, 2008;
111(12):
5446 - 5456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ouillette, H. Erba, L. Kujawski, M. Kaminski, K. Shedden, and S. N. Malek
Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14
Cancer Res.,
February 15, 2008;
68(4):
1012 - 1021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, and S. N. Malek
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia
Blood,
February 1, 2008;
111(3):
1584 - 1593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Majid, O. Tsoulakis, R. Walewska, S. Gesk, R. Siebert, D. B. J. Kennedy, and M. J. S. Dyer
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism
Blood,
January 15, 2008;
111(2):
874 - 877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kipps
Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment
ASCO Educational Book,
January 1, 2008;
2008(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Flynn and J. C. Byrd
Have We Forgotten the Purpose of Phase III Studies?
J. Clin. Oncol.,
December 10, 2007;
25(35):
5553 - 5555.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Krober, D. Kienle, P. Lichter, and H. Dohner
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival
Haematologica,
September 1, 2007;
92(9):
1242 - 1245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Shanafelt and N. E. Kay
Comprehensive Management of the CLL Patient: A Holistic Approach
Hematology,
January 1, 2007;
2007(1):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|